MediForge

An Industry 5.0 medicines manufacturing research hub

About

MediForge is a major new research programme led by CMAC to revolutionise the pharmaceutical landscape with its Industry 5.0 manufacturing system paradigm for sustainable, resilient, and human-centric medicines manufacture.

MediForge seeks to overcome the limitations of traditional Chemistry, Manufacturing, and Control (CMC) development processes which can be costly, time consuming and inflexible. In a time when the pharmaceutical industry faces significant challenges such as an aging population, rising costs, fragile global supply chains and the impacts of climate change, there is a critical need for a transformative approach to CMC.

Drivers

  • Meet the demand for affordable sustainable healthcare

  • Accelerate patient access to new medicines

  • Assure the resilient supply of quality medicines

  • Address the climate crisis and reach net zero goals

  • Enable the workforce of the future

MediForge, is a seven year, £11m programme funded by the Engineering and Physical Sciences Research Council (EPSRC), a division of UK Research and Innovation (UKRI), through their Manufacturing Hubs for a Sustainable Future Call 2.

Platform 1 - Learn

Platform 2 - Model

Platform 3 - Make

Platform 4 - Adapt

Partners

The programme been co-created in collaboration with partners at the University of Leeds, University of Sheffield, Glasgow School of Art, and Imperial College London. It is also supported by a global consortium of organisations and technology partners including AstraZeneca, Chiesi, Lilly, Pfizer, Roche, Sanofi, Takeda, UCB, CCDC, Bruker, NPL, Siemens and the Centre for Process Innovation (CPI).